Table 3.

Vaccine manufacturer and number of COVID-19 vaccine doses received between last menstrual period (LMP) and pregnancy end for each pregnancy (N = 23,265) reported by CDC COVID-19 Vaccine Pregnancy Registry participants, January 2021 – August 2022 (N = 23,249)^*.

	Manufacturer of first COVID-19 vaccine dose received**
	Pfizer-BioNTech N = 13,501 (58.0 %)		Moderna N = 9,040 (38.9 %)		Janssen N = 724 (3.1 %)		Overall N = 23,265
	n	(%)	n	(%)	n	(%)	n	(%)
Completed primary series by end of pregnancy***
Yes	12,318	(91.3)	7,910	(87.5)	724	(100.0)	20,952	(90.1)
No	1,183	(8.7)	1,130	(12.5)	0	(0.0)	2,313	(9.9)
Number of doses reported between LMP and pregnancy end including primary series and booster doses
One	1,488	(11.0)	1,385	(15.3)	687	(95.0)	3,560	(15.3)
Two	11,111	(82.3)	7,142	(79.0)	13	(1.8)	18,266	(78.5)
Three	613	(4.5)	256	(2.8)	0	(0.0)	869	(3.7)
None†	289	(2.1)	257	(2.8)	24	(3.2)	570	(2.5)

^*Vaccination through the end of pregnancy or, for participants lost to follow-up, through last report. 16 participants contributed more than one pregnancy; participants may have been fully vaccinated by the end of one pregnancy but not another and may have received a different number of vaccinations in each pregnancy.

^**Among participants who received a Pfizer-BioNTech or Moderna vaccination for their first dose, 10 participants received a vaccine from a different manufacturer for their second dose.

^***Primary series doses included doses 1 and 2 for mRNA vaccinations (Pfizer-BioNTech and Moderna) and dose 1 for Janssen vaccinations.

^†Participants who reported receiving at least one dose in the 30 days prior to their LMP but no doses between LMP and pregnancy end.